Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DISTINCTION: Dapagliflozin vs Sitagliptin in Chinese T2DM Patients on Insulin
NCT03959501Phase 4Completed
- Sponsor
- The University of Hong Kong
- Start
- Aug 2017
- Primary completion
- Oct 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of dapagliflozin in type 2 diabetes mellitus (T2DM), sponsored by The University of Hong Kong. Started Aug 2017; status: completed.
02
Drugs
dapagliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT03959501.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03959501.